';
CLOSE
Tags Posts tagged with "DDAP"

DDAP

0 134

On Tuesday, August 2, RCPA member Pyramid Healthcare joined the Department of Drug and Alcohol Programs (DDAP) to encourage use of the free and confidential Addiction Treatment Locator, Assessment, and Standards (ATLAS) platform in Pennsylvania.

ATLAS evaluates addiction treatment facilities’ use of evidence-based best practices based on the Shatterproof National Principles of Care, includes an assessment to understand the appropriate level of care, and offers an easy-to-use dashboard to allow those in need and their loved ones to search for and compare facilities using criteria such as location, services offered, and insurance accepted so they can find the best treatment for their unique needs. ATLAS is fully available in English and Spanish.

Founded in 1999 with headquarters in Altoona, Pyramid Healthcare is recognized as one of the largest, full-continuum providers of substance use treatment for adults and adolescents with 31 program locations in the commonwealth and 85 across seven eastern states.

“As a participating provider, Pyramid Healthcare proudly joins DDAP in support and promotion of ATLAS as an invaluable resource designed to bridge the gap between treatment access and client engagement within the commonwealth by helping individuals navigate available behavioral health treatment options that best fit their unique recovery needs,” said Jonathan Wolf, CEO of Pyramid Healthcare.

A multimedia package from the event is available online.

0 210

On July 7, 2022, Gov. Wolf signed Act 33 of 2022, which amends Act 63 of 1972 as it pertains to confidentiality of substance use disorder patient records. Act 33 incorporates federal confidential protections under the Health Insurance Portability and Accountability Act (HIPAA) and 42 CFR Part 2. Act 33, which took effect immediately, prohibits the Pennsylvania Department of Drug and Alcohol Programs (DDAP) from promulgating or enforcing a regulation that restricts any disclosure of records or information that is permitted by Act 33. DDAP is currently reviewing Act 33 to determine next steps as a regulatory agency and will be providing additional information and details on the DDAP website in the near future.

0 136

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) today announced the availability of $3 million in funding for entities to provide pregnancy support services to address the needs of pregnant and postpartum women with substance use disorder (SUD).

Eligible applicants can find the project summary and budget on the Funding Opportunities page of the DDAP website. Approximately three to five grants, up to $600,000 each, will be awarded to help provide services, streamline care, and assure that this population is connected with the most appropriate resources to reach long-term recovery.

All applications must be submitted via email by 11:59 pm on Friday, July 29, 2022. Applications will be competitively reviewed and scored based upon the applicant’s adherence to the funding announcement guidelines and a timely submission to DDAP.

The grants are part of $59 million in federal funding awarded to Pennsylvania through the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Substance Abuse Prevention and Treatment Block Grant Program.

Questions regarding the grants and the application process can be emailed to DDAP.

0 170

Today, the Department of Drug and Alcohol Programs (DDAP) was joined by national nonprofit Shatterproof and substance use disorder treatment provider Gaudenzia to announce the expansion of the free and confidential Addiction Treatment Locator, Assessment, and Standards Platform (ATLAS) to Pennsylvania.

ATLAS evaluates addiction treatment facilities’ use of evidence-based best practices based on the Shatterproof National Principles of Care, includes an assessment to understand the appropriate level of care, and offers an easy-to-use dashboard to allow those in need and their loved ones to search for and compare facilities using criteria such as location, services offered, and insurance accepted so they can find the best treatment for their unique needs. ATLAS is fully available in English and Spanish.

“We are grateful for ATLAS and the team at Shatterproof for making the submission process so easy,” said Dr. Dale Klatzker, President and CEO at Gaudenzia, Inc. “It is vital that we reduce barriers to treatment, and this tool provides an easy way for those in need to seek and quickly find a treatment option that will work best for them.”

Forty Gaudenzia treatment locations and a total of 515 substance use disorder treatment facilities across the state have submitted their information to be included in ATLAS. An additional open enrollment period for facilities who missed the first deadline will be available in fall 2022.

0 311

The Pennsylvania Department of State (DOS) has reversed course and extended its waiver allowing for an initial prescription of buprenorphine without an in-person physical exam. DOS had announced previously that the waiver would expire on June 30, 2022; however, DOS’s waiver will now continue until the last day of the federal public health emergency declaration, unless the exemptions are ended sooner by the Substance Abuse and Mental Health Services Administration (SAMHSA) or the US Drug Enforcement Administration (DEA).

On Sept. 4, 2020, DOS issued a waiver suspending the State Board of Medicine’s regulation at 49 Pa. Code § 16.92(b)(1), which requires an initial physical examination of a patient prior to prescribing buprenorphine for the treatment of opioid use disorder. This waiver was sought specifically to complement the Department of Drug and Alcohol Programs’ (DDAP) suspension of 28 Pa. Code § 715.9(a)(4) and “relates to Federal exemptions granted under the Federal public health emergency (PHE) declaration,” specifically the exemptions granted by the federal Substance Abuse and Mental Health Services Administration (SAMHSA) and the U.S. Drug Enforcement Agency (DEA).

Therefore, in accordance with section 2102-F(a.3) of the Pennsylvania Administrative Code of 1929 (amended by Act 14 of 2022), the Department of State’s waiver will continue until the last day of the federal public health emergency declaration, unless the exemptions are ended sooner by SAMHSA or the DEA. This waiver will not expire on June 30, 2022. More information about the federal public health emergency can be found here.

It is important to note that, to be considered within the acceptable and prevailing standard of care, the physician/prescriber must be following the applicable SAMHSA/DEA guidelines.

Pennsylvania has not received notification that the PHE will be terminated on July 15. The commonwealth expects the PHE to be extended again. If this occurs, this waiver and others tied to or related to the PHE will be extended until mid-October 2022.

Additional information:

0 274

In 2017, Governor Wolf signed Senate Bill 446 into law as Act 59, which gave the Department of Drug and Alcohol Programs (DDAP) the power and duty to license drug and alcohol recovery houses that receive referrals from state agencies or state-funded facilities or receive federal or state funding. That legislation gave DDAP the authority to take enforcement action and issue fines against operators of unlicensed recovery houses that receive public funding. Last December, DDAP announced that it had published regulations for the licensure program for drug and alcohol recovery houses was accepting applications. Those regulations stated that the provision for issuance of fines would not take effect until 180 days after they were published.

Thursday, June 9, marked 180 days after publication of the regulations. View Information Bulletin 01-22 for requirements for recovery house licensure.

DDAP’s goal is to continue working with recovery houses to attain licensure and will not be looking to penalize houses that are actively working through that process. DDAP and the Single County Authorities (SCAs) share a common goal of causing the least amount of disruption to the lives of individuals in recovery and are hopeful that more houses will continue to submit applications and increase the capacity of licensed recovery houses in Pennsylvania.

To that point, SCAs may continue to act on existing contracts with recovery houses regardless of licensure status through June 30, 2022. Beginning July 1, 2022, SCAs may not execute new contracts with unlicensed houses. For existing contracts that run beyond July 1, SCAs can no longer pay unlicensed houses and should be looking to transition residents to licensed houses and other living arrangements unless the house shows a timely, good faith effort to apply for licensure.

More information on the recovery house application process can be found on the DDAP website. DDAP is also offering a free one-day training workshop designed to answer the various questions associated with the application process. Participation in the workshop results in a decrease in the amount of time it takes to approve applications, resulting in the license being issued sooner to those applicants who participate. To register for the workshop, please email or call 717-783-8675.

123...11Next Page 1 of 11
© 2021 - Rehabilitation & Community Providers Association